---
title: 7 Ways Alzheimer’s DMTs Are Redefining Treatment and Patient Care
description: The global Alzheimer’s disease-modifying therapies (DMTs) market was estimated at $235.8 million in 2024 and is projected to reach $13.1 billion by 2030, growing at a CAGR of 67.8%
image: https://blog.bccresearch.com/hubfs/Blog_Images/alzheimer-blog2.jpg
---

[![BCC Research Blog](https://blog.bccresearch.com/hs-fs/hubfs/bcc_blog-2022/blogs/BCC_Research_Blog.png?width=188&height=45&name=BCC_Research_Blog.png "BCC Research Blog")](https://www.bccresearch.com/)

**

![7 Ways Alzheimer’s DMTs Are Redefining Treatment and Patient Care](https://blog.bccresearch.com/hubfs/Blog_Images/alzheimer-blog2.jpg "7 Ways Alzheimer’s DMTs Are Redefining Treatment and Patient Care")

# 7 Ways Alzheimer’s DMTs Are Redefining Treatment and Patient Care

![](https://blog.bccresearch.com/hubfs/karishma-arora.webp) [ Karishma Arora](https://blog.bccresearch.com/author/karishma-arora)

![date](https://blog.bccresearch.com/hubfs/bcc_blog-2022/blogs/date.svg)

Oct 13, 2025

[Blog](https://blog.bccresearch.com/) ** [pharmaceuticals](https://blog.bccresearch.com/topic/pharmaceuticals) ** 7 Ways Alzheimer’s DMTs Are Redefining Treatment and Patient Care

Alzheimer’s disease has long been one of the most challenging neurological disorders, affecting over 50 million people worldwide, with numbers expected to double by 2050. For decades, treatments mainly focused on easing symptoms, such as helping patients remember a name, a place, or a moment. But what if there was a way to slow, halt, or even prevent the disease itself? That’s where disease-modifying therapies (DMTs) come in.

## **Market Outlook**

The [**global Alzheimer’s disease-modifying therapies (DMTs) market**](https://www.bccresearch.com/market-research/pharmaceuticals/disease-modifying-therapies-for-alzheimers-disease-market.html) was estimated at $235.8 million in 2024 and is projected to reach $13.1 billion by 2030, growing at a CAGR of 67.8% during the forecast period. This rapid growth highlights the urgent need for therapies that go beyond symptom management, offering real potential to slow or modify the course of the disease.  

![Picture1-Oct-13-2025-12-03-16-6852-PM](https://blog.bccresearch.com/hs-fs/hubfs/Picture1-Oct-13-2025-12-03-16-6852-PM.jpg?width=1430&height=808&name=Picture1-Oct-13-2025-12-03-16-6852-PM.jpg)

 

### Disease-Modifying Therapies for Alzheimer’s Disease: Global Markets

The global Alzheimer’s disease-modifying therapies market was estimated to be around $235.8 million in 2024. The market is projected to reach $13.1 billion in 2030, growing at a CAGR of 67.8% during the forecast period.

[ Download Your Complimentary Report ](https://www.bccresearch.com/market-research/pharmaceuticals/disease-modifying-therapies-for-alzheimers-disease-market.html)

1. ** Understanding the Shift: From Symptom Relief to Disease Modification**

Traditional Alzheimer’s treatments have been like putting out fires, providing temporary relief without addressing the root cause. DMTs aim to target amyloid plaques, tau tangles, and neuroinflammation, addressing the underlying mechanisms of the disease. By slowing or halting progression, these therapies could fundamentally change patients’ experiences, allowing them to maintain their independence for longer and easing the burden on caregivers and healthcare systems.

Imagine a family watching a loved one stay active and engaged for years longer than previously possible, that is the promise researchers are pursuing.

1. ** The Science Behind DMTs**

- Developing DMTs relies on understanding Alzheimer’s at a molecular level. Advanced imaging and AI technologies now enable scientists to **identify disease markers before extensive brain damage occurs**, allowing for earlier and more precise interventions.

For example:

- **Anti-amyloid antibodies** help remove amyloid plaques from the brain.
- **Tau-targeting therapies** prevent tangles that disrupt neuronal function.
- **Neuroprotective and anti-inflammatory compounds** reduce further neuronal damage and support overall brain health.

These therapies are not only slowing disease progression, they are redefining the way Alzheimer's is treated.

1. ** Real-World Progress: Drugs and Clinical Trials**

Several DMTs are already making headlines:

- **Aducanumab:** This treatment has been approved in some regions and targets amyloid plaques in the brain. It has shown potential for slowing cognitive decline in patients with early-stage Alzheimer's disease.
- **Lecanemab:** This therapy demonstrated a 27% reduction in clinical decline during Phase 3 trials, offering hope to patients and their families.
- Other candidates that focus on tau proteins, inflammation, and synaptic repair are in late-stage trials, indicating a move toward more personalized treatment approaches.

These breakthroughs represent a shift from reactive symptom management to **proactive disease intervention**, thus giving patients more control over their journey.

1. ** Side Effects and Treatment Challenges**

While promising, DMTs are not without risks. Anti-amyloid therapies can cause brain swelling, microhemorrhages, and infusion reactions, which require careful monitoring through MRI scans. Additionally, the high costs and complex treatment schedules, such as frequent infusions, can also limit patient access.

Responses vary depending on genetics, disease stage, and overall health, meaning that a therapy effective for one patient may not work for another. Researchers are continually refining dosing protocols and safety measures to improve tolerability and increase accessibility.

1. ** Emerging Therapies**

The Alzheimer’s treatment landscape is rapidly evolving. Beyond amyloid and tau-targeted therapies, several **emerging strategies** are showing potential:

- **Neuroprotective agents:** These compounds help protect neurons from damage caused by oxidative stress and inflammation.
- **Gene therapies:** These approaches aim to correct genetic risk factors, such as APOE4, or enhance protective genes.
- **Immunomodulators:** These drugs adjust the immune system to reduce chronic neuroinflammation, a key driver of disease progression.
- **Synaptic repair strategies:** These treatments focus on restoring connections between neurons to improve cognitive function.

Clinical trials suggest that combination therapies targeting multiple disease pathways may be the most effective approach in the near future.

1. ** Case Studies: Disease-Modifying Therapies in Action**  
   **Aducanumab (Biogen, USA):** Patients treated with this therapy showed reduced amyloid accumulation and a slower cognitive decline, although careful monitoring was necessary to manage side effects such as ARIA (amyloid-related imaging abnormalities).  
   **Lecanemab (Eli Lilly, USA):** Phase 3 trials demonstrated that this treatment led to a 27% slower decline in early-stage Alzheimer’s patients, with improvements in daily functioning compared to a placebo group.  
   **AI + Imaging for Early Intervention (Banner Alzheimer’s Institute, USA):** Through the use of AI-enhanced PET imaging, researchers identified early amyloid accumulation in at-risk individuals. When investigational disease-modifying therapies (DMTs) were administered early, cognitive function was preserved longer compared to untreated participants.  
   **Dominantly Inherited Alzheimer Network (DIAN, Global):** Tracking genetically predisposed individuals, AI-guided interventions slowed biomarker progression before symptoms appeared, pointing toward a future of preventive care.  
   **Gene Therapy Trials (Europe):** AI-designed viral vectors are being tested to enhance protective APOE variants in early-stage patients, showing early signs of improved cognitive resilience.
2. ** The Future of Alzheimer’s Treatment**

DMTs are redefining the Alzheimer’s journey:

- Therapies are becoming personalized, based on genetics and disease stage.
- Preventive approaches and early-stage interventions may become standard practice.
- AI and big data are accelerating drug discovery, enabling faster development of effective treatments.

As research and clinical experience grow, Alzheimer’s may no longer be seen as an inevitable decline. Instead, DMTs offer hope for slower progression, better quality of life, and even potential prevention, transforming the outlook for patients, caregivers, and healthcare systems worldwide.

### Stay ahead of industry trends, build your market research strategy and more.

## Recent Posts

![Sweet Intelligence: How AI is Transforming the $180 Billion Confectionery Ingredients Game](https://blog.bccresearch.com/hs-fs/hubfs/AI-Generated%20Media/Images/Modern%20Confectionery%20Lab%20with%20AI%20Tech%20and%20Colorful%20Samples.png?quality=low&width=150&height=100&name=Modern%20Confectionery%20Lab%20with%20AI%20Tech%20and%20Colorful%20Samples.png)

#### [Sweet Intelligence: How AI is Transforming the $180 Billion Confectionery Ingredients Game 1 min. read | Featured, food-and-beverage, artificial intelligence technology](https://blog.bccresearch.com/how-ai-is-transforming-the-180-billion-confectionery-ingredients-game)

![AI Is Quietly Revolutionizing How We Make the Foam That's Everywhere](https://blog.bccresearch.com/hs-fs/hubfs/AI-Generated%20Media/Images/Foam%20Lab%20with%20Robotic%20Arm%20and%20Data%20Analytics.png?quality=low&width=150&height=100&name=Foam%20Lab%20with%20Robotic%20Arm%20and%20Data%20Analytics.png)

#### [AI Is Quietly Revolutionizing How We Make the Foam That's Everywhere 1 min. read | Semiconductor](https://blog.bccresearch.com/ai-is-quietly-revolutionizing-how-we-make-the-foam-thats-everywhere)

![Medical Plastics Meets AI: The Manufacturing Revolution Healthcare Didn't See Coming](https://blog.bccresearch.com/hs-fs/hubfs/AI-Generated%20Media/Images/Futuristic%20Manufacturing%20Facility%20with%20Robotic%20Arm%20and%20Holographic%20Interfaces.png?quality=low&width=150&height=100&name=Futuristic%20Manufacturing%20Facility%20with%20Robotic%20Arm%20and%20Holographic%20Interfaces.png)

#### [Medical Plastics Meets AI: The Manufacturing Revolution Healthcare Didn't See Coming 1 min. read | medical devices](https://blog.bccresearch.com/medical-plastics-meets-ai)

![The $1 Million Monthly Problem That AI Is Finally Solving in Clinical Trials](https://blog.bccresearch.com/hs-fs/hubfs/AI-Generated%20Media/Images/AIDriven%20Clinical%20Research%20Hub%20with%20Dynamic%20Data%20Visualization.png?quality=low&width=150&height=100&name=AIDriven%20Clinical%20Research%20Hub%20with%20Dynamic%20Data%20Visualization.png)

#### [The $1 Million Monthly Problem That AI Is Finally Solving in Clinical Trials 1 min. read | Featured, healthcare](https://blog.bccresearch.com/the-1-million-monthly-problem-that-ai-is-finally-solving-in-clinical-trials)

![Karishma Arora](https://blog.bccresearch.com/hubfs/karishma-arora.webp)

### Written By Karishma Arora

Karishma Arora is an Assistant Team Lead in Marketing Operations at BCC Research, with a master's degree in commerce. She is a passionate marketer with a knack for creativity and data-driven strategies.

### Related Content

[![Could AI Be the Missing Piece in Our $100 Billion Heart Health Crisis?](https://blog.bccresearch.com/hs-fs/hubfs/AI-Generated%20Media/Images/Healthcare%20Conference%20Focused%20on%20AIDriven%20Heart%20Health%20Innovations.png?quality=low&width=380&height=250&name=Healthcare%20Conference%20Focused%20on%20AIDriven%20Heart%20Health%20Innovations.png) 

](https://blog.bccresearch.com/100-billion-heart-health-crisis)

[ 1 min. read | ](https://blog.bccresearch.com/100-billion-heart-health-crisis)[pharmaceuticals](https://blog.bccresearch.com/topic/pharmaceuticals)

#### [Could AI Be the Missing Piece in Our $100 Billion Heart Health Crisis?](https://blog.bccresearch.com/100-billion-heart-health-crisis)

Heart disease remains the world's leading killer, claiming more lives annually t...

[Read more ![Read More](https://blog.bccresearch.com/hs-fs/hubfs/bcc_blog-2022/blogs/read_more_arrow.png?width=12&height=12&name=read_more_arrow.png) ](https://blog.bccresearch.com/100-billion-heart-health-crisis)

[![The $700,000 Animal Test That Companies Are Ditching for $15,000 Alternatives](https://blog.bccresearch.com/hs-fs/hubfs/AI-Generated%20Media/Images/Sleek%20Lab%20With%20OrganOnAChip%20And%20Data%20Screen.png?quality=low&width=380&height=250&name=Sleek%20Lab%20With%20OrganOnAChip%20And%20Data%20Screen.png) 

](https://blog.bccresearch.com/the-700000-animal-test-that-companies-are-ditching-for-15000-alternatives)

[ 1 min. read | ](https://blog.bccresearch.com/the-700000-animal-test-that-companies-are-ditching-for-15000-alternatives)[pharmaceuticals](https://blog.bccresearch.com/topic/pharmaceuticals)

#### [The $700,000 Animal Test That Companies Are Ditching for $15,000 Alternatives](https://blog.bccresearch.com/the-700000-animal-test-that-companies-are-ditching-for-15000-alternatives)

Here's a number that might surprise pharmaceutical executives: traditional anima...

[Read more ![Read More](https://blog.bccresearch.com/hs-fs/hubfs/bcc_blog-2022/blogs/read_more_arrow.png?width=12&height=12&name=read_more_arrow.png) ](https://blog.bccresearch.com/the-700000-animal-test-that-companies-are-ditching-for-15000-alternatives)

[![The $5-15 Million Question: How AI Is Making Animal Testing Obsolete](https://blog.bccresearch.com/hs-fs/hubfs/AI-Generated%20Media/Images/Futuristic%20Lab%20with%20Holographic%20Biology%20and%20AI%20Analytics.png?quality=low&width=380&height=250&name=Futuristic%20Lab%20with%20Holographic%20Biology%20and%20AI%20Analytics.png) 

](https://blog.bccresearch.com/the-5-15-million-question-how-ai-is-making-animal-testing-obsolete)

[ 1 min. read | ](https://blog.bccresearch.com/the-5-15-million-question-how-ai-is-making-animal-testing-obsolete)[pharmaceuticals](https://blog.bccresearch.com/topic/pharmaceuticals)

#### [The $5-15 Million Question: How AI Is Making Animal Testing Obsolete](https://blog.bccresearch.com/the-5-15-million-question-how-ai-is-making-animal-testing-obsolete)

Here's a staggering reality check for pharma: every failed compound that reaches...

[Read more ![Read More](https://blog.bccresearch.com/hs-fs/hubfs/bcc_blog-2022/blogs/read_more_arrow.png?width=12&height=12&name=read_more_arrow.png) ](https://blog.bccresearch.com/the-5-15-million-question-how-ai-is-making-animal-testing-obsolete)

![Guiding smart decisions every step of the way](https://blog.bccresearch.com/hs-fs/hubfs/Blog_Images/workaholic-hand-typing-keyboard-dark-late-night-with-computer.webp?width=1366&height=378&name=workaholic-hand-typing-keyboard-dark-late-night-with-computer.webp)

## Guiding smart decisions every step of the way

We are your trusted research partner, providing actionable insights and custom consulting across life sciences, advanced materials, and technology. Allow BCC Research to nurture your smartest business decisions today, tomorrow, and beyond.

[ Contact Us ](https://www.bccresearch.com/aboutus/contactus)

BCC Research provides objective, unbiased measurement and assessment of market opportunities with detailed market research reports. Our experienced industry analysts assess growth opportunities, market sizing, technologies, applications, supply chains and companies with the singular goal of helping you make informed business decisions, free of noise and hype.

### Stay Informed

#### Contact

- [**781-489-7301](tel:7814897301)
- [**info@bccresearch.com](mailto:info@bccresearch.com)

© 2023 BCC Research

[Privacy Policy](http://www.bccresearch.com/privacypolicy) |[Site Map](http://www.bccresearch.com/sitemap)

#### Connect With Us

[![BCC Research](https://blog.bccresearch.com/hs-fs/hubfs/BCCResearch%20-Feb2017/icon-linkedin-ftr.png?width=36&height=36&name=icon-linkedin-ftr.png) ](http://www.linkedin.com/company/bccresearch) [![BCC Research](https://blog.bccresearch.com/hs-fs/hubfs/BCCResearch%20-Feb2017/icon-email-ftr.png?width=36&height=36&name=icon-email-ftr.png) ](mailto:info@bccresearch.com) [![BCC Research](https://blog.bccresearch.com/hs-fs/hubfs/BCCResearch%20-Feb2017/icon-twitter-ftr.png?width=36&height=36&name=icon-twitter-ftr.png) ](https://twitter.com/bccresearch) [![BCC Research](https://blog.bccresearch.com/hs-fs/hubfs/bcc_blog-2022/blogs/youtube.png?width=36&height=36&name=youtube.png) ](https://www.youtube.com/user/bccresearch)

![money back guarantee](https://blog.bccresearch.com/hs-fs/hubfs/bcc_blog-2022/blogs/money-back.png?width=60&height=60&name=money-back.png)

```json
{
  "@context" : "https://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Karishma Arora",
    "url" : "https://blog.bccresearch.com/author/karishma-arora"
  },
  "dateModified" : "2025-10-13T13:00:01.351Z",
  "datePublished" : "2025-10-13T13:00:01.000Z",
  "headline" : "7 Ways Alzheimer’s DMTs Are Redefining Treatment and Patient Care",
  "image" : [ "https://blog.bccresearch.com/hubfs/Blog_Images/alzheimer-blog2.jpg" ],
  "mainEntityOfPage" : {
    "@id" : "https://blog.bccresearch.com/7-ways-alzheimers-dmts-are-redefining-treatment-and-patient-care",
    "@type" : "WebPage"
  },
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "url" : "https://blog.bccresearch.com/hubfs/Logos/BCC-Logo-PSD-REMOVED-WHITE-BCC.png"
    },
    "name" : "BCC Research LLC"
  }
}
```